ReviewMolecular biology reports2026
The multifaceted role of SOCS3 in colorectal cancer: molecular mechanisms and clinical implications.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a major cause of cancer-related mortality, particularly in advanced or metastatic disease. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway mediates cytokine-driven signaling, and its persistent activation contributes to tumor growth, invasion, immune escape, and therapeutic resistance. Suppressor of cytokine signaling 3 (SOCS3) is a key negative regulator of cytokine and growth factor signaling, especially the IL-6/JAK/STAT3 axis. This review summarizes the structure and physiological functions of SOCS3 and discusses its dysregulation in CRC initiation, progression, metastasis, prognosis, and treatment response. Current evidence indicates that SOCS3 is frequently downregulated in CRC through promoter methylation and post-transcriptional regulation by oncogenic microRNAs, leading to sustained STAT3 activation, increased proliferation, reduced apoptosis, and enhanced invasiveness. SOCS3 also interacts with MEK/ERK and PI3K/AKT signaling and influences the tumor microenvironment by regulating T-cell balance, PD-L1 expression, and macrophage activity. Clinically, reduced SOCS3 expression has been associated with lymph node metastasis, advanced TNM stage, and poorer prognosis, whereas higher SOCS3 levels may correlate with improved outcomes and chemosensitivity. Emerging therapeutic strategies include epigenetic modulation, JAK/STAT pathway inhibition, regulation of IL-6 signaling in adoptive T-cell therapy, AhR/IL-22 modulation, and FXR activation. Further translational studies are needed to validate SOCS3 as a biomarker and therapeutic target in CRC.
Indexed as
Identifiers
42525172What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.